524 related articles for article (PubMed ID: 25710482)
1. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
2. Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.
Szeląg M; Czerwoniec A; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2014 Oct; 740():417-20. PubMed ID: 25183399
[TBL] [Abstract][Full Text] [Related]
3. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
4. Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation validation.
Raj U; Kumar H; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2115-29. PubMed ID: 26471877
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.
Szelag M; Piaszyk-Borychowska A; Plens-Galaska M; Wesoly J; Bluyssen HA
Oncotarget; 2016 Jul; 7(30):48788-48812. PubMed ID: 27166190
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs.
Plens-Galaska M; Szelag M; Collado A; Marques P; Vallejo S; Ramos-González M; Wesoly J; Sanz MJ; Peiró C; Bluyssen HAR
Front Immunol; 2018; 9():2141. PubMed ID: 30283459
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.
Yesylevskyy SO; Ramseyer C; Pudlo M; Pallandre JR; Borg C
J Chem Inf Model; 2016 Aug; 56(8):1588-96. PubMed ID: 27479469
[TBL] [Abstract][Full Text] [Related]
8. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.
Smit LS; Meyer DJ; Billestrup N; Norstedt G; Schwartz J; Carter-Su C
Mol Endocrinol; 1996 May; 10(5):519-33. PubMed ID: 8732683
[TBL] [Abstract][Full Text] [Related]
9. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
10. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3.
Wiederkehr-Adam M; Ernst P; Müller K; Bieck E; Gombert FO; Ottl J; Graff P; Grossmüller F; Heim MH
J Biol Chem; 2003 May; 278(18):16117-28. PubMed ID: 12591923
[TBL] [Abstract][Full Text] [Related]
11. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains.
Gunning PT; Katt WP; Glenn M; Siddiquee K; Kim JS; Jove R; Sebti SM; Turkson J; Hamilton AD
Bioorg Med Chem Lett; 2007 Apr; 17(7):1875-8. PubMed ID: 17336521
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the binding of high affinity phosphopeptides to Stat3.
McMurray JS
Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
PLoS One; 2017; 12(6):e0178844. PubMed ID: 28636670
[TBL] [Abstract][Full Text] [Related]
14. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
15. STAT-3 inhibitors: state of the art and new horizons for cancer treatment.
Lavecchia A; Di Giovanni C; Novellino E
Curr Med Chem; 2011; 18(16):2359-75. PubMed ID: 21568920
[TBL] [Abstract][Full Text] [Related]
16. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening.
Liu LJ; Leung KH; Chan DS; Wang YT; Ma DL; Leung CH
Cell Death Dis; 2014 Jun; 5(6):e1293. PubMed ID: 24922077
[TBL] [Abstract][Full Text] [Related]
17. Efficient killing of SW480 colon carcinoma cells by a signal transducer and activator of transcription (STAT) 3 hairpin decoy oligodeoxynucleotide--interference with interferon-gamma-STAT1-mediated killing.
Tadlaoui Hbibi A; Laguillier C; Souissi I; Lesage D; Le Coquil S; Cao A; Metelev V; Baran-Marszak F; Fagard R
FEBS J; 2009 May; 276(9):2505-15. PubMed ID: 19476491
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the roles of STAT1 and STAT3 signal transduction pathways in mammalian lens development.
Ebong S; Chepelinsky AB; Robinson ML; Zhao H; Yu CR; Egwuagu CE
Mol Vis; 2004 Feb; 10():122-31. PubMed ID: 14978477
[TBL] [Abstract][Full Text] [Related]
19. Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.
Kong R; Bharadwaj U; Eckols TK; Kolosov M; Wu H; Cruz-Pavlovich FJS; Shaw A; Ifelayo OI; Zhao H; Kasembeli MM; Wong STC; Tweardy DJ
Pharmacol Res; 2021 Jul; 169():105637. PubMed ID: 33932608
[TBL] [Abstract][Full Text] [Related]
20. Chemical probes that competitively and selectively inhibit Stat3 activation.
Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]